Journal
ONCOTARGETS AND THERAPY
Volume 12, Issue -, Pages 11453-11464Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S223448
Keywords
miRNAs; miR-492; bladder cancer; GJB4; biomarker
Categories
Funding
- National Fund of China Foreign Experts Bureau [20172100003]
Ask authors/readers for more resources
Background: Bladder cancer is the most common urinary system malignancy in the United States and is characterized by its diverse prognosis and high recurrence rate. However, the molecular mechanisms underlying its progression remain unknown. Accumulating evidence suggests a critical role for miRNAs in bladder cancer progression. Methods and results: In this study, we found that miR-492 expression levels were significantly higher in bladder cancer tissue and the serum of bladder cancer patients by bioinformatics analysis and a panel of clinical samples. The results of receiver operating characteristic curve analysis suggested the potential diagnostic value of serum miR-492 for bladder cancer. In vitro and in vivo functional assays showed that knockdown of miR-492 suppressed proliferation and metastasis of bladder cancer cells. Gap junction beta-4 protein was predicted to be a direct target of miR-492, which was validated using a luciferase reporter assay. Further cellular functional assays showed that suppression of miR-492 abrogated bladder cancer cell proliferation and metastasis by targeting gap junction beta-4 protein. Conclusion: miR-492 promotes cancer progression by targeting GJB4 and is a novel biomarker for bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available